Diagenode

>>>   Click for Diagenode’s approach to COVID-19

ACTL6A suppresses p21 expression to enhance the epidermal squamous cell carcinoma phenotype.


Shrestha S, Adhikary G, Xu W, Kandasamy S, Eckert RL

Epidermal squamous cell carcinoma (SCC) is a common and highly invasive form of cancer. SCC arises due to ultraviolet light exposure and is associated with increased expression of pro-cancer genes and reduced expression of cancer suppressors. Actin-Like Protein 6A (ACTL6A, BAF53a) is an important protein subunit of the SWI/SNF epigenetic chromatin regulatory complex. ACTL6A is elevated in cancer cells and has been implicated as a driver of cancer cell proliferation and tumor growth. In the present study, we show that ACTL6A drives SCC cell proliferation, spheroid formation, invasion and migration, and that these activities are markedly reduced by ACTL6A knockdown. We further show that ACTL6A expression is associated with reduced levels of the p21 cyclin-dependent kinase inhibitor and tumor suppressor protein. Molecular studies show that ACTL6A interacts with p53 DNA response elements in the p21 gene promoter to suppress p21 promoter activity and mRNA and protein level. Additional studies show that an increase in p21 expression in ACTL6A knockdown cells is required for suppression of the SCC cell phenotype, suggesting that p21 is a mediator of ACTL6A action. We further show that this regulation is p53 independent. These findings suggest that ACTL6A suppresses p21 promoter activity to reduce p21 protein as a mechanism to maintain the aggressive epidermal SCC phenotype.

Tags
LowCell ChIP kit

Share this article

Published
July, 2020

Source

Products used in this publication

  • ChIP kit icon
    C01010073
    LowCell# ChIP kit protein G

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics